Vebreltinib (PLB1001) is a Type I MET inhibitor independently developed by Beijing Avistone Biotechnology Co., Ltd.. Vebreltinib monotherapy has demonstrated significant clinical potential, with three indications successfully developed to date:

(1)In November 2023, Vebreltinib was officially approved in China for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor (MET) exon 14 skipping alterations. Vebreltinib is a globally best-in-class drug for this indication.

(2)In April 2024, the National Medical Products Administration (NMPA) of China officially approved Vebreltinib for the treatment of adult patients with IDH mutant astrocytoma (WHO grade 4) with the PTPRZ1-MET fusion who have experienced treatment failure in prior therapies or glioblastoma with LGG history. This marks the world's first fully approved as first-in-class small molecule targeted therapy for MET inhibition for gliomas.

(3)In June 2025, the National Medical Products Administration (NMPA) of China officially approved Vebreltinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) amplification. This is the world's first approved targeted drug for the monotherapy of NSCLC patients with MET amplification, indicating the entry of MET-amplified NSCLC into the era of precision targeted therapy.

Andameritinib (PLB1004) is a third-generation small-molecule EGFR inhibitor with a novel structure. It can effectively and irreversibly target mutations such as EGFR exon 20 insertion and has the ability to penetrate the blood-brain barrier.

EGFR exon 20 insertion mutation is the third most common mutation form among non-small cell lung cancer patients with EGFR mutations, accounting for 4-12%. Patients carrying this gene mutation are resistant to the first-generation and second-generation EGFR inhibitors, as well as to the third-generation EGFR inhibitor, Osimertinib. The critical registration clinical study (KANNON Study) has preliminarily confirmed that Andameritinib has significant therapeutic effects and safety for patients carrying this gene mutation.

The combination of the MET inhibitor Vebreltinib and the EGFR inhibitor Andameritinib has potential clinical benefits for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations accompanied by secondary MET amplification/overexpression, or EGFR mutations with concurrent MET amplification/overexpression.

ANS01 is a Type II MET inhibitor. Its ingenious molecular design makes ANS01 promising to become the most successful and rarest next-generation MET inhibitor globally.

The combination of the next-generation MET inhibitor ANS01 and the EGFR inhibitor can address the drug resistance caused by MET mutations that emerge following MET inhibitor monotherapy or combination therapies.

ANS03 is capable of overcoming the problem of acquired drug resistance caused by previous Type I ROS1 inhibitors, and thus has a broader inhibitory spectrum of ROS1 kinase activity. This spectrum includes primary fusion mutations of the ROS1 kinase, as well as numerous secondary drug resistance mutations, such as the central β-sheet #6 (Cβ6) mutation (L2086F) of ROS1, SF mutations (G2032R and D2033N), and complex drug resistance mutations, etc.

The world-leading HER 20 mutation and HER 2 amplification inhibitor.

The world-leading 4^th generation EGFR-TKI.

The relevant information has not been disclosed.

The relevant information has not been disclosed.

The relevant information has not been disclosed.

The relevant information has not been disclosed.